Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

FDA approves a novel daily pill to treat stubborn high blood pressure

FDA approves AstraZeneca’s new kind of hypertension drug

BioPharma Dive1 min readAI-assisted summary
Editorial illustration for FDA approves AstraZeneca’s new kind of hypertension drug
Editorial illustration

Summary

The Food and Drug Administration has approved a first-of-its-kind treatment for adults who struggle to manage their high blood pressure. The new medication, called Baxfendy, is a once-daily tablet designed to be taken alongside standard blood pressure drugs. It offers a fresh option for patients whose condition has proven resistant to multiple other therapies.

What makes Baxfendy unique is how it works inside the body. Traditional medications tackle high blood pressure in various ways, but this new drug targets a specific enzyme responsible for producing a hormone called aldosterone. By blocking the synthesis of this hormone, Baxfendy effectively lowers a patient's seated blood pressure, which is the standard measurement doctors use in the clinic. In late-stage clinical trials, the drug performed significantly better than a placebo.

While the results are promising, the medication does come with a few limitations. Trial data showed that the drug is generally well tolerated, but it carries the risk of some mild adverse events. Patients taking Baxfendy might experience muscle spasms, dizziness, blood pressure that drops too low, or abnormal levels of sodium and potassium in their blood.

Why it matters.

This approval marks a major milestone for the treatment of hypertension, a condition that affects roughly 1.4 billion people worldwide. In the United States alone, tens of millions of patients continue to grapple with elevated blood pressure even after taking two or more standard medications. For these individuals, a drug that attacks the root cause of the problem through an entirely new mechanism could prevent serious cardiovascular complications down the line.

From a business perspective, Baxfendy is positioned to be a massive financial success for AstraZeneca. Company executives project the pill could generate at least $5 billion in annual sales. That number could eventually double to $10 billion if ongoing clinical studies prove the drug is also effective at treating other conditions like chronic kidney disease.

From the source

The story in numbers.

Projected minimum annual sales
$5 billion
Global hypertension patient population
1.4 billion
Upfront payment for CinCor Pharma acquisition
$1.3 billion
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
FDA approves a novel daily pill to treat stubborn high blood pressure — Daily Strand